Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
May 25, 2024 06:15 ET
|
Novartis Pharma AG
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
May 25, 2024 06:00 ET
|
Novartis Pharma AG
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical...
WOW (NYSE) ALERT: WideOpenWest’s $4.80 Per Share Offer from DigitalBridge is Under Investigation; Contact BFA Law to Discuss Your Rights
May 25, 2024 05:24 ET
|
Bleichmar Fonti & Auld
NEW YORK, May 25, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the (NYSE: WOW) WideOpenWest merger with DigitalBridge and Crestview. If you invested in...
SQSP (NYSE) ALERT: Squarespace’s $44 Per Share Buyout Offer From Permira is Under Investigation; Contact BFA Law to Discuss Your Rights
May 25, 2024 05:23 ET
|
Bleichmar Fonti & Auld
NEW YORK, May 25, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the (NYSE: SQSP) Squarespace buyout from Permira. If you invested in Squarespace you are...
SPT (NASDAQ) ALERT: Investors in Sprout Social that Lost Money when Stock Tumbled 40% Are Encouraged to Contact BFA Law by July Deadline in Class Action Lawsuit
May 25, 2024 05:20 ET
|
Bleichmar Fonti & Auld
NEW YORK, May 25, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 12, 2024 deadline in the (Nasdaq: SPT) Sprout Social Securities Class Action...
CERE (NASDAQ) ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation; Contact BFA Law to Discuss Your Rights
May 25, 2024 05:18 ET
|
Bleichmar Fonti & Auld
NEW YORK, May 25, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between (Nasdaq: CERE) Cerevel Therapeutics Holdings, Inc. and AbbVie, Inc. If...
CAE (NYSE) ALERT: Investors in CAE, Inc. that Lost Money when Stock Tumbled 5% are Encouraged to Contact BFA Law About Your Rights
May 25, 2024 05:16 ET
|
Bleichmar Fonti & Auld
NEW YORK, May 25, 2024 (GLOBE NEWSWIRE) -- Top securities law firm Bleichmar Fonti & Auld LLP announces an investigation into CAE, Inc. (NYSE: CAE) for potential violations of the federal...
MacDonald Mines Withdraws Previously Announced Scadding Gold Project Assays Pending Further Review
May 24, 2024 22:58 ET
|
MacDonald Mines Exploration Ltd.
TORONTO, May 24, 2024 (GLOBE NEWSWIRE) -- MacDonald Mines Exploration Ltd. (TSX-V: BMK, OTC: MCDMF) (“MacDonald Mines” or the “Company”) has discovered inconsistencies in certain assay results from...
Regenx Provides Bi-Weekly Update on Status of Management Cease Trade Order
May 24, 2024 21:45 ET
|
Regenx Tech Corp.
EDMONTON, Alberta, May 24, 2024 (GLOBE NEWSWIRE) -- Regenx Tech Corp., (the "Company" or "Regenx") (CSE: RGX) (OTCQB: RGXTF) (FSE: YRS WKN:A2DSW3) is providing this bi-weekly update on the status of...
Merus : publication d’un résumé sur l’association pétosemtamab + pembrolizumab dans le traitement de 1re ligne du CETC r/m lors de l’édition 2024 du congrès ASCO®
May 24, 2024 21:30 ET
|
Merus N.V.
- Taux de réponse de 60 % observé auprès de 10 patients évaluables - Profil d’innocuité favorable chez 26 patients recrutés à la date de clôture du résumé, sans aucune observation de...
- May 24, 2024 20:18 ET Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB)
- May 24, 2024 20:06 ET Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Direct Digital Holdings, Inc. (DRCT)